Healthcare R&D: How Much Should Advanced Economies Invest in the Future of Health?

Healthcare Is No Longer Simply an Expenditure

Healthcare is increasingly becoming one of the world’s most important
innovation-driven economic sectors, connecting medicine,
biotechnology, pharmaceuticals, medical devices, diagnostics, artificial
intelligence, genomics, digital health and advanced manufacturing.

The critical question for governments, healthcare investors and healthcare
companies is therefore no longer simply:

How much does a country spend on healthcare?

The more strategic question is:

How much of that healthcare economy is being converted into
research, innovation and future value creation?

This distinction is becoming increasingly important as developed economies
compete for leadership in biotechnology, precision medicine, AI-enabled
healthcare, advanced diagnostics and next-generation pharmaceuticals.

1. Healthcare Already Represents a Major Share of GDP

The scale of the healthcare economy is enormous.

According to the latest OECD
Health at a Glance 2025, OECD countries allocated approximately
9.3% of GDP to healthcare in 2024.
The United States was an exceptional outlier at approximately
17.2%, followed by Germany at approximately
12.3%.

A large group of developed economies spend between 10% and 12% of GDP on
healthcare.

Yet only a relatively small proportion of this enormous economic resource
is directed toward R&D.

That is where the strategic opportunity begins.

2. How Much Goes Into Healthcare R&D?

There is an important measurement challenge.

There is no single internationally standardized indicator called
“healthcare R&D as % of healthcare expenditure”
covering every component of health innovation.

Health-related R&D can include:

• Pharmaceutical R&D
• Biotechnology
• Medical devices
• Diagnostics
• Clinical trials
• Basic biomedical research
• Translational research
• Health artificial intelligence
• Digital health
• Genomics
• Public-health research
• University medical research
• Government-funded health research
• Hospital and clinical research

The OECD therefore reports several complementary measures rather than one
universal healthcare-R&D ratio.

OECD data show that governments in 35 OECD countries collectively budgeted
approximately US$73 billion for health-related R&D
in 2022.

The United States alone accounted for approximately
US$49.5 billion.

At the same time, the pharmaceutical industry invested approximately
US$129 billion in R&D globally in 2022.

3. The United States: The World’s Healthcare Innovation Engine

The United States provides perhaps the clearest example of the relationship
between healthcare expenditure and innovation.

The country spent approximately 17.2% of GDP on healthcare in
2024, by far the highest proportion among OECD economies.

In 2022:

• Government health-related R&D budgets were approximately
  US$49.5 billion.
• Pharmaceutical industry R&D was approximately
  US$103.9 billion in the United States.

Pharmaceutical companies therefore invested more than twice the amount of
the US government health-related R&D budget.

4. Europe: Smaller Than the US — But Highly Concentrated

Europe presents a different innovation model.

The European Union invested approximately
€403 billion in total R&D in 2024, equivalent to
approximately 2.24% of GDP.

Business enterprises represented approximately
66.5% of total EU R&D expenditure.

Healthcare innovation, however, is highly concentrated in several
economies, particularly:

• Switzerland
• Belgium
• Denmark
• Germany
• Sweden
• United Kingdom

Pharmaceutical R&D has historically represented particularly high
proportions of GDP in countries such as Switzerland and Belgium.

5. Germany: A Large Healthcare Economy With Strong R&D Capacity

Germany spent approximately 12.3% of GDP on healthcare in
2024, making it one of the highest healthcare-spending economies
in the OECD.

Germany also maintains one of Europe’s strongest overall R&D systems.
Total R&D intensity reached approximately
3.1% of GDP in 2024.

The strategic issue is therefore not whether Germany invests heavily in
R&D. It clearly does.

The more important question is how effectively healthcare R&D is
connected to its pharmaceutical, biotechnology, medical-device,
engineering and hospital ecosystems.

6. Japan: Healthcare Meets Advanced Technology

Japan represents another important model.

It combines:

• A rapidly ageing population
• High healthcare expenditure
• Strong pharmaceutical companies
• Advanced medical technology
• Robotics
• Artificial intelligence
• Biomedical research

Japan budgeted approximately US$3.3 billion for
government health-related R&D in 2022.

Japan demonstrates how demographic pressure can become an innovation
opportunity.

7. Switzerland: A Small Country With an Outsized Innovation Economy

Switzerland is one of the most interesting examples for healthcare
investors.

Despite its relatively small population, Switzerland has developed an
extraordinarily strong pharmaceutical and life-sciences ecosystem.

Pharmaceutical R&D has historically reached approximately
0.6–0.8% of GDP, depending on the year and methodology.

8. The Bigger Benchmark: Total National R&D

Healthcare R&D must also be viewed in the context of total national
R&D.

OECD estimates indicate that overall R&D expenditure across OECD
economies reached approximately 2.7% of GDP in 2024.

The EU average was approximately 2.24% of GDP.

Selected R&D-Intensive Economies

9. The Most Useful Healthcare R&D Benchmark

For investors and policymakers, it would be misleading to use one single
number such as:

“Healthcare R&D should equal X% of GDP.”

A much stronger approach is to monitor several complementary ratios.

Ratio 1 — Healthcare Intensity

Total Healthcare Expenditure ÷ GDP

This measures the economic importance of healthcare.

Ratio 2 — National Innovation Intensity

Total R&D Expenditure ÷ GDP

This measures how strongly the economy invests in future productivity.

Ratio 3 — Healthcare Innovation Intensity

Health-related R&D Expenditure ÷ GDP

This measures how much of national economic resources are directed toward
future healthcare innovation.

Ratio 4 — Healthcare R&D Intensity

Health-related R&D ÷ Total Healthcare Expenditure

10. A Practical International Benchmark

Based on international OECD patterns covering government health-related
R&D and pharmaceutical R&D, a useful strategic framework can be
developed.

Note: These ranges are not an official OECD classification. They are a
strategic business framework derived from international patterns in
government health-related and pharmaceutical R&D.

11. Why Healthcare R&D Matters to Investors

The significance of R&D is not simply the amount of money invested.
It is the economic multiplier generated by that investment.

A successful health innovation ecosystem can create value through:

For example, investment in oncology research can generate value across
multiple sectors:

• New pharmaceuticals
• Companion diagnostics
• Molecular testing
• AI diagnostics
• Clinical trials
• Precision medicine platforms
• Healthcare data businesses
• Specialised manufacturing
• Medical tourism
• International licensing revenues

12. The Opportunity for Emerging Healthcare Markets

This has major implications for emerging healthcare markets such as
Egypt and other developing economies.

Many emerging markets focus primarily on:

• Hospitals
• Clinics
• Pharmacies
• Medical equipment
• Healthcare insurance

These investments are essential, but they primarily represent the
consumption side of healthcare.

The next stage is to build the production side of healthcare
knowledge.

This requires investment in:

1. Clinical research centres
2. Translational medicine centres
3. Biotechnology laboratories
4. Genomics platforms
5. AI-health laboratories
6. Medical-device innovation centres
7. Digital-health laboratories
8. Academic medical centres
9. Clinical-trial networks
10. Healthcare venture-capital funds

13. What Should Be the Target?

For an emerging economy seeking to become a regional healthcare and
life-sciences hub, a reasonable long-term strategic ambition could be
progressively building toward:

while simultaneously increasing:

The critical issue is that this should not be achieved through government
spending alone.

The Ideal Innovation Model

14. R&D Is Not a Cost Centre — It Is a Value-Creation Engine

Perhaps the most important change in thinking is managerial.

Traditional healthcare accounting often treats R&D as an expense.

A modern healthcare strategy should increasingly treat R&D as:

The potential return can come through:

• New products
• Patents
• Licensing
• New companies
• Higher productivity
• Better clinical outcomes
• Reduced cost of care
• International exports
• Foreign investment
• Medical tourism
• Healthcare data assets
• Strategic competitive advantage

Healthcare companies that understand this shift will increasingly behave
less like traditional service providers and more like
technology and life-science companies.

15. The New Healthcare Investment Equation

A country can spend 12–17% of GDP on healthcare and still have a
relatively weak innovation ecosystem.

Conversely, a country with a smaller healthcare market can become a global
life-sciences leader if it creates an efficient ecosystem connecting:

The United States demonstrates the scale of this model.
Switzerland demonstrates the power of concentration.
Germany demonstrates the importance of industrial R&D.
Denmark and Belgium demonstrate the power of pharmaceutical
specialisation.
Japan demonstrates the opportunity created by demographic transformation.
South Korea demonstrates how technology investment can rapidly transform
an innovation ecosystem.

Conclusion: The Next Competition Is for Healthcare Innovation

The global healthcare market is already enormous.

OECD countries collectively spend approximately
9.3% of GDP on healthcare, while the United States reaches
approximately 17.2%.

But the countries that will dominate the next decade will not necessarily
be those that spend the most.

They will be the countries that

convert the greatest proportion of healthcare expenditure into
innovation, intellectual property, productivity and scalable businesses.

For policymakers, healthcare executives and investors, the objective should
no longer be simply to build more hospitals.

The objective should be to build an ecosystem capable of producing:

• The next medicine
• The next diagnostic platform
• The next healthcare AI company
• The next medical device
• The next biotechnology breakthrough
• The next generation of healthcare businesses